Echo IQ, an Australian healthcare company, has achieved a significant milestone with the U.S. FDA granting 510(k) clearance for its AI-based solution, EchoSolv AS. The software supports the diagnosis of severe aortic stenosis, a critical heart valve condition. This clearance follows Echo IQ's U.S. market entry two years ago and its subsequent FDA application in May.
EchoSolv AS leverages artificial intelligence to automate the identification of aortic stenosis based on clinical guidelines and phenotype analysis. Several studies from both Australia and the U.S. have demonstrated the solution's high accuracy, with Echo IQ claiming a detection rate of up to 97%. This accomplishment coincides with a recent A$7.1 million capital raise, which will fuel further development of heart disease diagnostic tools and global expansion.
The company, now focusing on U.S. commercialization, has initiated partnership discussions with hospital groups and is pursuing licensing opportunities with device manufacturers. Echo IQ is also working on securing reimbursement codes for its software, creating incentives for broader adoption in U.S. hospitals. The company is also in the process of recruiting a U.S.-based CEO.
Click here to read the original news story.